Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome

Table 4 Characteristics of individuals with a comorbid inflammatory condition based on medication exposure

Characteristic	Exposed	Unexposed	P value
	n = 9 (39.5)	n = 12 (60.5)
Current age (yr), mean ± SD	54.2 ± 20	53.6 ± 12.4	0.7
Gender, n (%)
Female	4 (44.4)	8 (66.7)	0.4
Race, n (%)
Caucasian	7 (77.8)	10 (83.3)	1
Others	2 (22.2)	2(16.7)
Smoking Status, n (%)
Former/current	4 (44.4)	5 (41.7)	1
Never smoked	4 (55.6)	7 (58.3)
Previous history of cancer, n (%)	2 (22.2)	2 (16.7)	1
Family history of cancer, n (%)
LS specific cancer	6 (66.7)	5 (41.7)	0.39
All other cancers	6 (44.4)	8 (66.7)	0.4
Duration of Follow up, (yr), median (IQR)	10.0 (9.0-22.0)	8.5 (5.3-17.3)	0.38
Comorbid disease, n (%)	3 (33.3)	4 (33.3)	1
Crohn’s disease	2 (22.2)	3 (25.0)
Ulcerative colitis	1 (11.1)	1 (8.3)
Rheumatic disease, n (%)	6 (66.7)	8 (66.7)	1
Pathogenic variant
MLH1	2 (22.2)	3 (25.0)
MSH2	2 (22.2)	1 (8.3)
MSH6	0 (0)	2 (16.7)	0.68
PMS2	2 (22.2)	2 (16.7)
MSI-H	3 (33.3)	4 (33.3)
Cancer after CID diagnosis	7 (77.8)	5 (41.7)	0.18
Time to Cancer After Diagnosis of CID, (yr), median (IQR)	5.0 (2.0-16.0)	5.0 (1.0-10.5)	0.64
Age at Diagnosis of first cancer (yr), median (IQR)	49 (23.0-54.0)	48 (44.0-50.0)	0.99

HNPCC: Hereditary non-polyposis colorectal cancer; LS: Lynch syndrome; MMRPV: Mismatch repair pathogenic variant; CID: Comorbid inflammatory disease.